Law360, New York (October 07, 2009) -- Weighing whether to adopt or extend a poison pill as part of a takeover defense strategy has become an increasingly complicated process for public companies, and recent pushes for corporate governance reforms promise to make the decision even more complex, experts say.
It’s a decision that a number of public companies have to face this year: More than 200 companies have a decade-old poison pill set to expire, according to data released...
